Topics

Do Early Changes to Dosing of T-DM1 Affect Outcomes in HER2-Positive Breast Cancer?

20:00 EDT 14 Aug 2019 | Cancer Networks

A new analysis looked at how dose interruptions or reductions of ado-trastuzumab emtansine in the treatment of advanced HER2-positive breast cancer impacted long-term survival outcomes.

Original Article: Do Early Changes to Dosing of T-DM1 Affect Outcomes in HER2-Positive Breast Cancer?

NEXT ARTICLE

More From BioPortfolio on "Do Early Changes to Dosing of T-DM1 Affect Outcomes in HER2-Positive Breast Cancer?"

Quick Search

Relevant Topic

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...